Mirati Trials
When you press “Start Questionnaire”, you will be presented with a few questions about your or the patient’s condition and treatment history. Your answers to the questionnaire will then be …
Combination with Pembrolizumab (PD-1) | Mirati Therapeutics, Inc.
Leave a Reply You must be logged in to post a comment.
Presented at AACR -NCI-EORTC International Conference on Molecular Targets
• Optimization of the warhead reactivity and naphthyl substituent of tool compound MRTX1257 led to the optimized compound MRTX849 with favorable human PK and dose predictions. • Dose …
KRYSTAL-16: A Phase 1/1b Trial of Adagrasib(MRTX849) in Combination with Palbociclib in Patients with Advanced Solid Tumors with KRASG12CMutation
• Targeted KRAS G12C inhibitors will improve the outcome for a subset of these patients • Additional therapies that enhance KRAS inhibition and/or target additional mutations may …
Selectively targeting KRAS mutant alleles: contribution of both cell autonomous and pro-immunogenic MOAs in an expanded spectrum of human cancers
PXWDQW WXPRU PRGHOV ‡ 7KH HIILFDF\ RI 057; FDQ EH PRQLWRUHG YLD DQDO\VLV RI '863 EORRG WUDQVFULSW OHYHOV DQG LV FXUUHQWO\ EHLQJ …
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS …
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
Mocetinostat With Vinorelbine in Children, Adolescents & …
This phase I trial studies the side effects and best dose of mocetinostat when given together with vinorelbine to see how well it works in treating children, adolescents, and young adults with …